BioPharmSignal logoBioPharmSignal

Biotech News

Fulgent Reports Third Quarter 2025 Financial Results

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.Earnings

Revenue of $84.1 million , growing 17% year-over-year Raising Full Year 2025 Revenue Guidance to $325.0 million Raising Full Year 2025 EPS Guidance to GAAP loss of approximately ( $1.70 ) per share and Non-GAAP income of $0.30 per share GAAP gross profit of $35.5 million , or GAAP gross margin of

Related news

FLGTFulgent Genetics, Inc.2026-07-30 20:05 EST

Fulgent Reports Second Quarter 2026 Financial Results

FLGTFulgent Genetics, Inc.2026-07-09 20:05 EST

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

SNDXSyndax Pharmaceuticals2026-08-04 20:01 EST

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

BMYBMYBristol-Myers Squibb Company2026-07-30 10:59 EST

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

REGNRegeneron Pharmaceuticals2026-07-30 10:30 EST

Regeneron Reports Second Quarter 2026 Financial and Operating Results

View all latest news

Fulgent Genetics, Inc.

Precision Medicine Business Fulgent Genetics operates a laboratory-services business alongside a therapeutic-development portfolio. The company aims to combine diagnostic capabilities with drug development to become an integrated precision-medicine organization. Laboratory Services Fulgent provides technical laboratory testing and...

Recent company news

FLGTFulgent Genetics, Inc.2026-07-30 20:05 EST

Fulgent Reports Second Quarter 2026 Financial Results

FLGTFulgent Genetics, Inc.2026-07-09 20:05 EST

Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

FLGTFulgent Genetics, Inc.2026-06-01 23:00 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

FLGTFulgent Genetics, Inc.2026-05-21 21:03 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

FLGTFulgent Genetics, Inc.2026-05-01 11:00 EST

Fulgent Reports First Quarter 2026 Financial Results

Stock data

Close
18.55 USD
Market cap
531.09M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States